Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Arcalyst (rilonacept) Market Value Analysis: What Growth Lies Ahead Over The Forecast Period?
The market size for arcalyst (rilonacept) has witnessed substantial growth in recent years. It is projected to increase from $0.24 million in 2025 to $0.26 million in 2026, at a compound annual growth rate (CAGR) of 7.3%. This historical growth can be linked to the identification of il 1 driven diseases, a scarcity of alternative options for rare inflammatory conditions, robust clinical outcomes with rilonacept, regulatory approvals for orphan indications, and the adoption of biologic therapies by specialists.
The arcalyst (rilonacept) market is poised for significant expansion over the next few years. It is forecast to achieve a valuation of $0.33 million by 2030, growing at a compound annual growth rate (CAGR) of 6.5%. This anticipated growth during the forecast period is driven by factors such as an increase in the diagnosis of autoinflammatory syndromes, the broadening of its applications into additional indications, improvements in genetic screening, greater accessibility to biologic therapies, and rising investments in treatments for rare diseases. Major developments expected throughout this period include the increased adoption of IL-1 blocking therapies, wider use in rare autoinflammatory disorders, the expansion of long-term inflammation control treatments, a heightened emphasis on targeted cytokine inhibition, and enhanced management strategies for chronic inflammatory conditions.
Get A Free Sample Report With In-Depth Market Insights:
Arcalyst (rilonacept) Market Growth Factors: What’s Supporting Expansion?
The arcalyst (rilonacept) market is anticipated to grow due to the increasing demand for personalized medicines. This medical approach customizes treatment and healthcare decisions to the unique characteristics of each patient, such as their genetics, environment, and lifestyle. The rising demand for personalized medicine is attributed to its potential to enhance treatment effectiveness, mitigate adverse effects, and address individual variations in disease progression and drug response. As personalized medicine gains prominence, there is increased awareness and improved diagnostic tools for identifying rare and genetically driven conditions. This leads to more individuals being diagnosed with conditions treatable by Arcalyst, consequently boosting the drug’s demand. For instance, in February 2024, a report by the US-based non-profit organization Personalized Medicine Coalition (PMC) indicated that the FDA approved 16 new personalized treatments for rare disease patients in 2023, marking a significant increase from the six approvals in 2022. Additionally, according to PMC in February 2023, the FDA approved 12 new personalized medicines in 2022, making it the eighth consecutive year that personalized medicines represented at least a quarter of all new drug approvals. Hence, the escalating demand for personalized medicines is driving the expansion of the arcalyst (rilonacept) market.
Arcalyst (rilonacept) Market Segment Breakdown: Which Categories Lead On Revenue?
The arcalyst (rilonacept) market covered in this report is segmented –
1) By Type: Lyophilized, Liquid
2) By Indication: Cryopyrin-Associated Periodic Syndromes (CAPS), Deficiency Of Interleukin-1 Receptor Antagonist (DIRA), Other Indications
3) By Distribution Channels: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By End User: Adult Patients, Pediatric Patients
Arcalyst (rilonacept) Market Industry Trends: What’s Reshaping Demand?
Leading companies in the Arcalyst (rilonacept) market are concentrating on expanding its indications, specifically including interleukin 1 trap therapy for recurrent pericarditis, to secure a competitive edge. Interleukin-1 trap therapy is a medical approach designed to block excessive IL-1 proteins, thereby alleviating harmful inflammation in the body. For example, in May 2024, Kiniksa Pharmaceuticals, a US based biopharmaceutical company, obtained FDA approval for Arcalyst in recurrent pericarditis. This approval featured weekly subcutaneous dosing, a dual IL 1a/IL 1ß blockade, and a positive safety profile for long-term administration. This development significantly broadens Arcalyst’s potential patient population beyond its initial Cryopyrin-Associated Periodic Syndromes (CAPS) indication. However, greater usage might expose the medication to increased market rivalry, continuous long-term safety surveillance, and closer scrutiny from payors.
Arcalyst (rilonacept) Market Leading Players And Competitive Positioning
Major companies operating in the arcalyst (rilonacept) market are Regeneron Pharmaceuticals Inc., Kiniksa Pharmaceuticals Ltd.
View The Full Arcalyst (rilonacept) Market Report:
Arcalyst (rilonacept) Market Geographic Analysis: Where Is Demand Rising Fastest?
North America was the largest region in the arcalyst (rilonacept) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the arcalyst (rilonacept) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
